UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 238

Sortiert nach

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

British journal of cancer, 2014-11, Vol.111 (10), p.1932-1944

2014

Volltextzugriff (PDF)

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival

British journal of cancer, 2012-06, Vol.106 (12), p.1967-1975

2012

Volltextzugriff (PDF)

Glucose activates the multifunctional Ca2+/calmodulin-dependent protein kinase II in isolated rat pancreatic islets

The Journal of biological chemistry, 1994-02, Vol.269 (7), p.4947-4952

1994

Volltextzugriff (PDF)

Inhibition of insulin secretion by KN-62, a specific inhibitor of the multifunctional Ca2+/calmodulin-dependent protein kinase II

Biochemical and biophysical research communications, 1992-11, Vol.189 (1), p.128-133

1992

Volltextzugriff (PDF)

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives

International journal of women's health, 2016, Vol.8 (Issue 1), p.59-75

2016

Volltextzugriff (PDF)

Sexual health in women treated for cervical cancer: Characteristics and correlates

Gynecologic oncology, 2007-02, Vol.104 (2), p.428-434

2007

Volltextzugriff (PDF)

RELATIONSHIP BETWEEN POLYMORPHISMS IN THE PROGESTERONE AND TYPE I TGF-BETA RECEPTORS AND OVARIAN CANCER RISK

International journal of gynecological cancer, 2004-09, Vol.14 (Suppl 1), p.8-8

2004

Volltextzugriff (PDF)

Abstract OT2-09-01: Pilot study of denosumab in BRCA1/2 mutation carriers scheduling for risk-reducing salpingo-oophorectomy

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT2-09-01-OT2-09-01

2019

Volltextzugriff (PDF)

A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: Ovarian cancer (OC) subset—A study of the Princess Margaret, Mayo, Southeast phase II, and California Cancer (CCCP) N01 Consortia NCI#8233

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5015-5015

2011

Volltextzugriff (PDF)

First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3102-3102

2011

Volltextzugriff (PDF)

First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3001-3001

2010

Volltextzugriff (PDF)

Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.5049-5049

2010

Volltextzugriff (PDF)

Factors Associated With Sexual Desire and Satisfaction after Gynecologic Cancer

Psycho-oncology (Chichester, England), 2012-02, Vol.21, p.14

2012

Volltextzugriff (PDF)

Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5546-5546

2009

Volltextzugriff (PDF)

Progesterone Receptor Promoter +331A Polymorphism is Associated with a Reduced Risk of Endometrioid and Clear Cell Ovarian Cancers

Cancer epidemiology, biomarkers & prevention, 2004-12, Vol.13 (12), p.2141-2147

2004

Volltextzugriff (PDF)

Polymorphisms in BRCA1 and BRCA2 and Risk of Epithelial Ovarian Cancer

Clinical cancer research, 2003-10, Vol.9 (12), p.4396-4403

2003

Volltextzugriff (PDF)

Stage IIB–IVB Cervical Adenocarcinoma: Prognostic Factors and Survival

Gynecologic oncology, 2002-01, Vol.84 (1), p.115-119

2002

Volltextzugriff (PDF)

Molecular aspects of ovarian cancer

Best practice & research. Clinical obstetrics & gynaecology, 2002-08, Vol.16 (4), p.483-497

2002

Volltextzugriff (PDF)

No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina

Cancer epidemiology, biomarkers & prevention, 2003-03, Vol.12 (3), p.226-227

2003

Volltextzugriff (PDF)

The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers

Clinical and experimental allergy, 1990-01, Vol.20 (1), p.45-51

1990

Volltextzugriff (PDF)

Plated contacts for solar cells with superior adhesion strength to screen printed solar cells

Frontiers in Energy, 2017-03, Vol.11 (1), p.72-77

2017

Volltextzugriff (PDF)

Controlled Investigations in Baboons ( Papio cynocephalus ) on Transmission of SV -5 Virus by Contact

Nature (London), 1967-02, Vol.213 (5078), p.827-828

1967

Volltextzugriff (PDF)

Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer

Journal of the Society for Gynecologic Investigation, 2003-09, Vol.10 (6), p.381-387

Wenham, R

2003

Volltextzugriff (PDF)

Rapid Stabilization of High-Performance Multicrystalline P-type Silicon PERC Cells

IEEE journal of photovoltaics, 2016-11, Vol.6 (6), p.1473-1479

2016

Volltextzugriff (PDF)

Matrix Metalloproteinase-1 Gene Promoter Polymorphism and Risk of Ovarian Cancer

Journal of the Society for Gynecologic Investigation, 2003-09, Vol.10 (6), p.381-387

2003

Volltextzugriff (PDF)

1 – 25 von 238

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(200)
Mit Volltextzugriff
(212)

Publikationsform

Sprache

Englisch
(238)
Japanisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(165)
Life Sciences & Biomedicine
(83)
Humans
(73)
Technology
(67)
Physical Sciences
(57)
Energy & Fuels
(52)
Female
(49)
Materials Science
(49)
Physics
(48)
Physics, Applied
(45)
Photovoltaic Cells
(43)
Male
(39)
Materials Science, Multidisciplinary
(39)
Middle Aged
(39)
Aged
(38)
Biological And Medical Sciences
(34)
Solar Energy
(34)
Engineering
(31)
Medical Sciences
(31)
Engineering, Electrical & Electronic
(30)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival

Glucose activates the multifunctional Ca2+/calmodulin-dependent protein kinase II in isolated rat pancreatic islets

Inhibition of insulin secretion by KN-62, a specific inhibitor of the multifunctional Ca2+/calmodulin-dependent protein kinase II

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives

Sexual health in women treated for cervical cancer: Characteristics and correlates

RELATIONSHIP BETWEEN POLYMORPHISMS IN THE PROGESTERONE AND TYPE I TGF-BETA RECEPTORS AND OVARIAN CANCER RISK

Abstract OT2-09-01: Pilot study of denosumab in BRCA1/2 mutation carriers scheduling for risk-reducing salpingo-oophorectomy

A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: Ovarian cancer (OC) subset—A study of the Princess Margaret, Mayo, Southeast phase II, and California Cancer (CCCP) N01 Consortia NCI#8233

First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc)

First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers

Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer

Factors Associated With Sexual Desire and Satisfaction after Gynecologic Cancer

Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube

Progesterone Receptor Promoter +331A Polymorphism is Associated with a Reduced Risk of Endometrioid and Clear Cell Ovarian Cancers

Polymorphisms in BRCA1 and BRCA2 and Risk of Epithelial Ovarian Cancer

Stage IIB–IVB Cervical Adenocarcinoma: Prognostic Factors and Survival

Molecular aspects of ovarian cancer

No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina

The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers

Plated contacts for solar cells with superior adhesion strength to screen printed solar cells

Controlled Investigations in Baboons ( Papio cynocephalus ) on Transmission of SV -5 Virus by Contact

Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer

Rapid Stabilization of High-Performance Multicrystalline P-type Silicon PERC Cells

Matrix Metalloproteinase-1 Gene Promoter Polymorphism and Risk of Ovarian Cancer

Suchergebnisse filtern